Journal: International Journal of Molecular Sciences

Article Title: Naked and Decorated Nanoparticles Containing H 2 S-Releasing Doxorubicin: Preparation, Characterization and Assessment of Their Antitumoral Efficiency on Various Resistant Tumor Cells

doi: 10.3390/ijms231911555

Figure Lengend Snippet: Microemulsion compositions.

Article Snippet: Hyaluronic acid sodium salt 1600 kDa (HA) was purchased from Farmalabor (Barletta, Italy), stearylamine (ST), cetyltrimethylammonium bromide (CTAB), ethyl acetate (EA), propylene glycol, benzyl alcohol, Pluronic ® F68 (PL F68), polyvinyl alcohol 9000 (PVA 9000), and Kollidon ® 25 (PVP) were from Merck (Darmstadt, Germany), Epikuron ® 200 (phosphatidylcholine 92%) was from Cargill (Minneapolis, MN, USA), doxorubicin hydrochloride (DOXO) was purchased from APAC Pharmaceutical (Columbia, MD, USA), Cremophor ® RH60 (PEG-60 hydrogenated castor oil) from BASF (Ludwigshafen am Rhein, Germany), taurocholic acid sodium salt (NaTC) and glycocholic acid sodium salt (NaGC) were from ICN Biomedicals (Aurora, OH, USA), and trilaurin and tristearin from Alfa-Aesar (Ward Hill, MA, USA).

Techniques:

Journal: Acta Pharmaceutica Sinica. B

Article Title: Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

doi: 10.1016/j.apsb.2021.04.001

Figure Lengend Snippet: Chronological number of publications about oral delivery of PPs by searching Web of Science to Nov. 9th, 2020 using the phrases of “oral AND (absorption OR delivery) AND (protein∗ OR peptide∗)”.

Article Snippet: The ChronotropicTM platform technologies developed by Dexcel Pharma Technologies, Ltd. (Jerusalem, Israel) combine the protease inhibitor (camostat mesilate) and absorption enhancer (sodium glycocholate) to improve the oral bioavailability of insulin .

Techniques:

Journal: Acta Pharmaceutica Sinica. B

Article Title: Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

doi: 10.1016/j.apsb.2021.04.001

Figure Lengend Snippet: Flow chart of the general considerations in enhancement of oral bioavailability of PPs. There are various technologies based on three rationales including stabilization, absorption enhancement and mucus-related technologies.

Article Snippet: The ChronotropicTM platform technologies developed by Dexcel Pharma Technologies, Ltd. (Jerusalem, Israel) combine the protease inhibitor (camostat mesilate) and absorption enhancer (sodium glycocholate) to improve the oral bioavailability of insulin .

Techniques:

Journal: Acta Pharmaceutica Sinica. B

Article Title: Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

doi: 10.1016/j.apsb.2021.04.001

Figure Lengend Snippet: Schematic illustration of structure of intestinal patch and administration device, and in vivo mechanism of adhesion, drug release and absorption across intestinal epithelium. Reprinted with the permission from Ref. . Copyright © 2016 Springer.

Article Snippet: The ChronotropicTM platform technologies developed by Dexcel Pharma Technologies, Ltd. (Jerusalem, Israel) combine the protease inhibitor (camostat mesilate) and absorption enhancer (sodium glycocholate) to improve the oral bioavailability of insulin .

Techniques: In Vivo

Journal: Acta Pharmaceutica Sinica. B

Article Title: Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

doi: 10.1016/j.apsb.2021.04.001

Figure Lengend Snippet: The schematic illustration of mechanisms of absorption enhancers including transcellular and paracellular pathways. Reprinted with the permission from Ref. 21. Copyright © 2016 Elsevier.

Article Snippet: The ChronotropicTM platform technologies developed by Dexcel Pharma Technologies, Ltd. (Jerusalem, Israel) combine the protease inhibitor (camostat mesilate) and absorption enhancer (sodium glycocholate) to improve the oral bioavailability of insulin .

Techniques:

Journal: Acta Pharmaceutica Sinica. B

Article Title: Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

doi: 10.1016/j.apsb.2021.04.001

Figure Lengend Snippet: Representative examples of nanotechnology-based strategies used for enhancing oral absorption of PPs.

Article Snippet: The ChronotropicTM platform technologies developed by Dexcel Pharma Technologies, Ltd. (Jerusalem, Israel) combine the protease inhibitor (camostat mesilate) and absorption enhancer (sodium glycocholate) to improve the oral bioavailability of insulin .

Techniques: Modification, Liposomes, Drug discovery